These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 19330934)

  • 1. Diagnosis scoring for clinical identification of children with heterozygous familial hypercholesterolemia.
    Benlian P; Turquet A; Carrat F; Amsellem S; Sanchez L; Briffaut D; Girardet JP
    J Pediatr Gastroenterol Nutr; 2009 Apr; 48(4):456-63. PubMed ID: 19330934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compound heterozygous familial hypercholesterolemia in a Chinese boy with a de novo and transmitted low-density lipoprotein receptor mutation.
    Ma Y; Gong Y; Garg A; Zhou H
    J Clin Lipidol; 2018; 12(1):230-235.e6. PubMed ID: 29233637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.
    Grenkowitz T; Kassner U; Wühle-Demuth M; Salewsky B; Rosada A; Zemojtel T; Hopfenmüller W; Isermann B; Borucki K; Heigl F; Laufs U; Wagner S; Kleber ME; Binner P; März W; Steinhagen-Thiessen E; Demuth I
    Atherosclerosis; 2016 Oct; 253():88-93. PubMed ID: 27596133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
    Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
    Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
    Jensen HK
    Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of low-density lipoprotein receptor gene mutations in patients with a clinical diagnosis of familial combined hyperlipidemia in a clinical setting.
    Civeira F; Jarauta E; Cenarro A; García-Otín AL; Tejedor D; Zambón D; Mallen M; Ros E; Pocoví M
    J Am Coll Cardiol; 2008 Nov; 52(19):1546-53. PubMed ID: 19007590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homozygous Familial Hypercholesterolemia in Spain: Prevalence and Phenotype-Genotype Relationship.
    Sánchez-Hernández RM; Civeira F; Stef M; Perez-Calahorra S; Almagro F; Plana N; Novoa FJ; Sáenz-Aranzubía P; Mosquera D; Soler C; Fuentes FJ; Brito-Casillas Y; Real JT; Blanco-Vaca F; Ascaso JF; Pocovi M
    Circ Cardiovasc Genet; 2016 Dec; 9(6):504-510. PubMed ID: 27784735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spectrum of low-density lipoprotein receptor (LDLR) mutations in a cohort of Sri Lankan patients with familial hypercholesterolemia - a preliminary report.
    Paththinige CS; Rajapakse JRDK; Constantine GR; Sem KP; Singaraja RR; Jayasekara RW; Dissanayake VHW
    Lipids Health Dis; 2018 May; 17(1):100. PubMed ID: 29720182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial hypercholesterolemia: molecular, biochemical, and clinical characterization of a French-Canadian pediatric population.
    Assouline L; Levy E; Feoli-Fonseca JC; Godbout C; Lambert M
    Pediatrics; 1995 Aug; 96(2 Pt 1):239-46. PubMed ID: 7630677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of ezetimibe and high-dose of statin treatment on LDL levels in patients with heterozygous familial hypercholesterolemia.
    Pitsavos C; Skoumas I; Tousoulis D; Metalinos G; Masoura C; Chrysohoou C; Papadimitriou L; Giotsas N; Toutouza M; Antoniades C; Stefanadis C
    Int J Cardiol; 2009 May; 134(2):280-1. PubMed ID: 18353459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterozygous familial hypercholesterolemia in children: low-density lipoprotein receptor mutational analysis and variation in the expression of plasma lipoprotein-lipid concentrations.
    Torres AL; Moorjani S; Vohl MC; Gagné C; Lamarche B; Brun LD; Lupien PJ; Després JP
    Atherosclerosis; 1996 Sep; 126(1):163-71. PubMed ID: 8879444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is new in familial hypercholesterolemia?
    Santos RD; Maranhao RC
    Curr Opin Lipidol; 2014 Jun; 25(3):183-8. PubMed ID: 24699416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetically Confirmed Familial Hypercholesterolemia in Patients With Acute Coronary Syndrome.
    Amor-Salamanca A; Castillo S; Gonzalez-Vioque E; Dominguez F; Quintana L; Lluís-Ganella C; Escudier JM; Ortega J; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
    J Am Coll Cardiol; 2017 Oct; 70(14):1732-1740. PubMed ID: 28958330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.
    Glueck CJ; Shah P; Goldenberg N; Prince M; Lee K; Jetty V; Kumar A; Goldenberg M; Wang P
    Lipids Health Dis; 2016 Mar; 15():55. PubMed ID: 26968977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia.
    Santos PC; Morgan AC; Jannes CE; Turolla L; Krieger JE; Santos RD; Pereira AC
    Atherosclerosis; 2014 Mar; 233(1):206-10. PubMed ID: 24529145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Approaches in Detection and Treatment of Familial Hypercholesterolemia.
    Hartgers ML; Ray KK; Hovingh GK
    Curr Cardiol Rep; 2015 Dec; 17(12):109. PubMed ID: 26482752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid phenotype and heritage pattern in families with genetic hypercholesterolemia not related to LDLR, APOB, PCSK9, or APOE.
    Jarauta E; Pérez-Ruiz MR; Pérez-Calahorra S; Mateo-Gallego R; Cenarro A; Cofán M; Ros E; Civeira F; Tejedor MT
    J Clin Lipidol; 2016; 10(6):1397-1405.e2. PubMed ID: 27919357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of clinical diagnostic criteria for familial hypercholesterolemia genetic testing in Poland.
    Mickiewicz A; Chmara M; Futema M; Fijalkowski M; Chlebus K; Galaska R; Bandurski T; Pajkowski M; Zuk M; Wasag B; Limon J; Rynkiewicz A; Gruchala M
    Atherosclerosis; 2016 Jun; 249():52-8. PubMed ID: 27062410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.